Personalis, Inc. (PSNL) Prelim. Q4 Revenue Tops Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFR
5. FFAI
6. TSLA
7. META
8. FICO
9. CART
10. LLY

Go back to Personalis, Inc. (PSNL) Prelim. Q4 Revenue Tops Consensus

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

January 4, 2023 4:01 PM EST

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022.

Personalis estimates revenue of approximately $16.7 million for the fourth quarter of 2022 and approximately $65.0 million for the full year of 2022, which exceeds the companys previous full year guidance range of $63.0 to $64.0 million.

Fourth Quarter Highlights

Preliminary revenue from biopharma and other customers is estimated to be $15.8 million in the fourth quarter of 2022 compared with $15.4 million... More